H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Verrica Pharmaceuticals to $12 from $11 and keeps a Buy rating on the shares after Ycanth was approved ahead of the July 23 FDA action date. The analyst sees peak sales approaching $300M and sees Verrica as undervalued here on the Ycanth molluscum contagiosum opportunity alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
- Biotech Alert: Searches spiking for these stocks today
- Needham upgrades Verrica Pharmaceuticals to Buy on Ycanth opportunity
- Verrica Pharmaceuticals price target raised to $14 from $11 at RBC Capital
- Verrica Pharmaceuticals upgraded to Buy from Hold at Needham